Business Wire

U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ ...
Medical News Today

Tecartus dosage

Tecartus (brexucabtagene autoleucel) is a brand-name drug that’s prescribed for certain types of lymphoma and leukemia in adults. Tecartus is given as an intravenous (IV) infusion in a specialized ...
Monthly Prescribing Reference

Tecartus Approved for Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL. The Food and Drug Administration has approved ...
Seeking Alpha

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

– ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients – – Real-World Evidence Analysis Shows High ...
Nasdaq

Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued ...
Nasdaq

New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma

Kite, a Gilead Company, today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus™ in adult patients with relapsed or refractory mantle cell lymphoma. At a median follow-up of 17.5 ...